Henriëtte Levenga

Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients

Willemijn Hobo, Leonie Strobbe, Frans Maas et al. · Cancer Immunology Immunotherapy · 2013 · 69 citations · Full text

Medicine, Immunology, Oncology +16

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

Sabina Kersting, Julie Dubois, Kazem Nasserinejad et al. · The Lancet Haematology · 2022 · 31 citations · Full text

Medicine, Hematology, Pharmacology +3

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Lina van der Straten, Claudia A.M. Stege, Sabina Kersting et al. · Blood · 2023 · 28 citations · Full text

Medicine, Geriatric Medicine, Pharmacotherapy +6

A Polymorphism in the Splice Donor Site of ZNF419 Results in the Novel Renal Cell Carcinoma-Associated Minor Histocompatibility Antigen ZAPHIR

Kelly Broen, Henriëtte Levenga, Johanna C. M. Vos et al. · PLoS ONE · 2011 · 25 citations · Full text

Life Sciences, Immunology, Oncology +16

Partial T Cell-Depleted Allogeneic Stem Cell Transplantation following Reduced-Intensity Conditioning Creates a Platform for Immunotherapy with Donor Lymphocyte Infusion and Recipient Dendritic Cell Vaccination in Multiple Myeloma

Henriëtte Levenga, Nicolaas Schaap, Frans Maas et al. · Biology of Blood and Marrow Transplantation · 2009 · 23 citations · Full text

Life Sciences, Immunology, Immunotherapy +15